Arrowhead Pharmaceuticals (ARWR) Free Cash Flow (2010 - 2026)
Arrowhead Pharmaceuticals (ARWR) posted Free Cash Flow of $81.9 million for Q1 2026, up 622.47% on a QoQ basis from $11.3 million in Q4 2025, and down 81.8% year-over-year from $449.8 million in Q1 2025.
Arrowhead Pharmaceuticals (ARWR) Free Cash Flow (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals' Free Cash Flow history runs 17 years deep, the most recent figure standing at $81.9 million for Q1 2026.
- Quarterly Free Cash Flow fell 81.8% year-over-year to $81.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$28.5 million (down 396.82% YoY) and the FY2025 annual result came in at $179.3 million, up 129.67% from the prior year.
- Free Cash Flow was $81.9 million for Q1 2026 at Arrowhead Pharmaceuticals, up from $11.3 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $449.8 million in Q1 2025 and bottomed at -$187.0 million in Q3 2023.
- A 5-year average of -$46.1 million and a median of -$101.4 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow tumbled 535.44% — and 2025, when it soared 455.72%.
- Arrowhead Pharmaceuticals' Free Cash Flow stood at -$114.4 million in 2022, then sank by 62.98% to -$186.5 million in 2023, then rose by 20.19% to -$148.8 million in 2024, then surged by 107.61% to $11.3 million in 2025, then jumped by 622.47% to $81.9 million in 2026.
- Business Quant data shows ARWR's Free Cash Flow at $81.9 million in Q1 2026, $11.3 million in Q4 2025, and $20.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Arrowhead Pharmaceuticals | 11.98 Bn | 10.18 Bn | - | 81.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 81.88 Mn |
| Mar 31, 2026 | 81.88 Mn |
| Dec 31, 2025 | 11.33 Mn |
| Dec 31, 2025 | 11.33 Mn |
| Sep 30, 2025 | 20.56 Mn |
| Sep 30, 2025 | 20.56 Mn |
| Jun 30, 2025 | -142.25 Mn |
| Jun 30, 2025 | -142.25 Mn |
| Mar 31, 2025 | 449.81 Mn |
| Mar 31, 2025 | 449.81 Mn |
| Dec 31, 2024 | -148.85 Mn |
| Dec 31, 2024 | -148.85 Mn |
| Sep 30, 2024 | -161.51 Mn |
| Sep 30, 2024 | -161.51 Mn |
| Jun 30, 2024 | -129.87 Mn |
| Jun 30, 2024 | -129.87 Mn |
| Mar 31, 2024 | -126.45 Mn |
| Mar 31, 2024 | -126.45 Mn |
| Dec 31, 2023 | -186.50 Mn |
| Dec 31, 2023 | -186.50 Mn |